疼痛管理デバイスの世界市場：2025年～2033年

疼痛管理デバイスの世界市場は2024年に38億米ドルに達し、2033年までには83億米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは9.2%で成長する見込みです。

疼痛管理デバイスは、慢性および急性の痛みを和らげ、患者のQOLを向上させ、オピオイドなどの薬物治療への依存を軽減するために設計された専門医療ツールです。電気刺激、温熱療法、凍結療法、ドラッグデリバリーシステムなど様々な技術を駆使し、痛みを直接または間接的に緩和します。

疼痛管理デバイスは、オピオイド中毒のような、従来の方法では不十分であったり、大きなリスクを伴ったりする症状に対して効果的な解決策を提供することで、現代のヘルスケアにおいて重要な役割を果たしています。患者に痛みをコントロールする力を与え、臨床や家庭での疼痛管理の効率を高めます。

世界の疼痛管理デバイス市場は、慢性疼痛疾患の有病率の増加、技術の進歩、非侵襲的治療オプションへの選好の高まりなどの要因によって、大きな成長を遂げています。例えば、米国疾病予防管理センター（CDC）によると、2021年には米国成人の推定20.9％（5,160万人）が慢性疼痛を経験し、6.9％（1,710万人）が影響の大きい慢性疼痛を経験しており、効果的な疼痛管理デバイスの需要を牽引しています。

市場力学：

促進要因と抑制要因

疼痛管理デバイスの技術的進歩の高まり

疼痛管理デバイスにおける技術進歩の高まりは、疼痛管理デバイス市場の成長を大きく後押ししており、予測期間中も市場を牽引していくと予想されます。脊髄刺激や末梢神経刺激のような技術はより高度になっており、刺激パラメータを正確に制御することで標的を絞った疼痛緩和を提供しています。こうした進歩は痛みの緩和を改善するだけでなく、より個別化された設定を可能にすることで患者の満足度を高めます。

例えば、Abbottは2023年1月、糖尿病の衰弱性合併症である有痛性糖尿病性末梢神経障害（DPN）を治療するための脊髄刺激（SCS）システム「Proclaim XR」の米国食品医薬品局（FDA）承認を取得しました。プロクレイムXR SCSシステムは、経口薬などの従来の治療アプローチに代わる選択肢を必要としているDPN患者を救済することができます。また、Proclaim XR SCSシステムによる治療を受ける人は、AbbottのNeuroSphereバーチャルクリニックを利用することができます。このバーチャルクリニックは、コネクテッド・ケア・アプリであり、医師とのコミュニケーションを可能にし、遠隔で治療の調整を受けることができます。

疼痛管理デバイスにおけるAIの活用は、パーソナライズされた治療計画を推進しています。これらの技術はリアルタイムで患者のデータを分析し、最適な痛みの緩和のために機器のパラメーターを調整します。例えば、2024年9月、Nevro Corp.は、脊髄刺激における唯一のAI駆動技術であるHFX AdaptivAIを搭載したHFX iQを米国食品医薬品局（FDA）から承認され、限定的に市場投入すると発表しました。

イメージングとガイダンスシステムの技術的進歩により、低侵襲および非侵襲の処置が標準になりつつあります。例えば、2024年9月、Zynex Inc.は新しいTensWave装置のFDA認可を発表しました。TensWaveは処方箋のみで、疼痛管理におけるZynexの技術革新の遺産を基盤としています。TensWaveは、患者の日常生活に簡単に取り入れることができる、ユーザーフレンドリーでポータブルなデザインです。この装置は、TENS（経皮的電気神経刺激）療法による効果的な疼痛緩和を目的としており、投薬治療を必要とせずに慢性および急性の疼痛を軽減することが臨床的に証明されています。

疼痛管理デバイスの高価格

疼痛管理デバイスのコストが高いことが、予測期間中の市場成長の妨げになると予想されます。脊髄刺激装置、神経刺激装置、輸液ポンプなどの高度な疼痛管理デバイスのコストは、多くの患者にとって法外なものである可能性があります。特に、こうした機器に対する保険適用が限られているか、存在しない国ではなおさらです。

たとえば、Physician Partners of Americaによると、脊髄刺激装置の価格は、診療所によって7,000米ドルから1万米ドルです。また、Boston Scientificの脊髄刺激装置は、新しいモデルで約1万9,000米ドルもします。

これらの装置、特に脳深部刺激装置や手技のコストが高いことは、潜在的な患者の大部分にとって、アクセスや購入のしやすさを制限し、市場の成長を妨げる大きな要因となっています。この経済的障壁は、特に中低所得地域における導入率に影響を与え、ヘルスケアプロバイダーと患者の双方に影響を及ぼします。

例えば、国立衛生研究所（National Institute of Health）によると、2024年のインフレ・通貨調整後のDBS装置の平均費用は21,496.07米ドル＋-8,944.16米ドル、手術のみの費用は14,685.22米ドル＋-8,479.66米ドル、手術の総費用は40,942.85米ドル＋-17,987.43米ドル、1年間の追跡調査までの治療費総額は47,632.27米ドル＋-23,067.08米ドルでした。

目次

第1章 市場イントロダクションと範囲

• 報告書の目的
• 調査範囲と定義
• 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

• 市場のハイライトと戦略的ポイント
• 主な動向と将来の予測
• スニペット：製品タイプ別
• スニペット：用途別
• スニペット：エンドユーザー別
• スニペット：地域別

第3章 市場力学

• 影響要因
  • 促進要因
    • 疼痛管理デバイスにおける技術進歩の高まり
  • 抑制要因
    • 疼痛管理デバイスのコストが高い
  • 機会
  • 影響分析

第4章 戦略的洞察と業界展望

• 市場のリーダーと先駆者
  • 新たな先駆者と著名なプレーヤー
  • 最大の売上を誇るブランドを確立したリーダー
  • 確立された製品を持つ市場リーダー
• 新興スタートアップ企業と主要イノベーター
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格市場力学

第5章 疼痛管理デバイス市場、製品タイプ別

• 神経刺激装置
  • 脊髄刺激装置
  • 末梢神経刺激装置
  • 脳深部刺激装置
• アブレーション装置
  • 凍結アブレーション装置
  • 高周波アブレーション装置
• 輸液ポンプ
• 電気刺激装置

第6章 疼痛管理デバイス市場、用途別

• 神経障害性疼痛
• がんの痛み
• 筋骨格系の痛み
• 片頭痛の痛み
• その他

第7章 疼痛管理デバイス市場、エンドユーザー別

• 病院
• 専門クリニック
• 在宅医療
• 理学療法センター
• その他

第8章 疼痛管理デバイス市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第9章 競合情勢と市場ポジショニング

• 競合概要と主要な市場企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併、買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第10章 企業プロファイル

• Medtronic plc
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
  • SWOT分析
• Boston Scientific Corporation
• Abbott Laboratories
• Stryker Corporation
• Nevro Corp
• Aleva Neurotherapeutics
• Zynex Inc.
• ICU Medical, Inc.
• inomed Medizintechnik GmbH
• Enovis Corporation

第11章 前提条件と調査手法

• データ収集方法
• データの三角測量
• 予測技術
• データの検証と検証

第12章 付録

The global pain management devices market reached US$ 3.8 billion in 2024 and is expected to reach US$ 8.3 billion by 2033, growing at a CAGR of 9.2% during the forecast period 2025-2033.

Pain management devices are specialized medical tools designed to alleviate chronic and acute pain, improve patient quality of life, and reduce dependency on pharmacological treatments such as opioids. These devices employ various technologies, including electrical stimulation, heat therapy, cryotherapy, and drug delivery systems, to target pain at its source and provide relief either directly or indirectly.

Pain management devices play a crucial role in modern healthcare by providing effective solutions for conditions where traditional methods may be insufficient or carry significant risks, such as opioid addiction. They empower patients with better control over their pain and enhance the efficiency of pain management in clinical and home settings.

The global pain management devices market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic pain conditions, technological advancements and a growing preference for non-invasive treatment options. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2021, an estimated 20.9% of U.S. adults (51.6 million persons) experienced chronic pain, and 6.9% (17.1 million persons) experienced high-impact chronic pain, driving the demand for effective pain management devices.

Market Dynamics: Drivers & Restraints

Rising technological advancements in pain management devices

The rising technological advancements in pain management devices are significantly driving the growth of the Pain Management Devices market and are expected to drive the market over the forecast period. Technologies like Spinal Cord Stimulation and Peripheral Nerve Stimulation are becoming more advanced, providing targeted pain relief with precise control over stimulation parameters. These advancements not only improve pain relief but also enhance patient satisfaction by allowing more personalized settings.

For instance, in January 2023, Abbott cleared the U.S. Food and Drug Administration (FDA) approval for its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. People who receive therapy from the Proclaim XR SCS system will also be able to use Abbott's NeuroSphere Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely.

The use of AI in pain management devices is driving personalized treatment plans. These technologies analyze patient data in real time, adjusting device parameters for optimal pain relief. For instance, in September 2024, Nevro Corp. announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI, the Only AI-driven technology in spinal cord stimulation, a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.

Minimally invasive and non-invasive procedures are becoming the norm due to technological advancements in imaging and guidance systems. For instance, in September 2024, Zynex Inc. announced FDA clearance of its new TensWave device. The TensWave device, by prescription only, builds on Zynex's strong legacy of innovation in pain management. It offers a user-friendly, portable design that can be easily integrated into patients' daily routines. The device aims to provide effective pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which has been clinically proven to reduce chronic and acute pain without needing medication.

High cost of pain management devices

The high cost of pain management devices is expected to hamper the growth of the market over the forecast period. The cost of advanced pain management devices such as spinal cord stimulators, neurostimulation devices, and infusion pumps can be prohibitive for many patients. These devices often require upfront payments that are beyond the reach of many individuals, especially in countries where insurance coverage for such devices is limited or nonexistent.

For instance, according to the Physician Partners of America, the price for a spinal cord stimulator ranges from $7,000-$10,000 depending on the practice. Additionally, a Boston Scientific Spinal Cord Stimulator costs around $19,000 for newer models.

The high cost of these devices especially fro deep brain stimulation devices and procedures is a significant factor that hampers market growth by limiting access and affordability for a large segment of potential patients. This financial barrier affects adoption rates, particularly in low- and middle-income regions and impacts both healthcare providers and patients.

For instance, according to the National Institute of Health, 2024, the inflation and currency-adjusted mean cost of the DBS device was USD 21,496.07 +- USD 8,944.16, the cost of surgery alone was USD 14,685.22 +- USD 8,479.66, the total cost of surgery was USD 40,942.85 +- USD 17,987.43 and the total cost of treatment until 1 year of follow-up was USD 47,632.27 +- USD 23,067.08.

Segment Analysis

The global pain management devices market is segmented based on product type, application, end-user and region.

Product Type:

The neurostimulation devices segment is expected to dominate the pain management devices market share

Neurostimulation devices, such as Spinal Cord Stimulation (SCS) and Deep Brain Stimulation (DBS), are highly effective in managing chronic pain by targeting specific pain pathways. This targeted approach allows for customized treatment settings that adapt to the patient's specific pain pattern.

For instance, in January 2024, Abbott received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC DBS system, the world's smallest rechargeable deep brain stimulation (DBS) device with remote programming. The Liberta RC DBS system requires the fewest recharges of any FDA-approved DBS system, needing only 10 recharge sessions a year for most people.

Neurostimulation devices are used to treat a broad spectrum of chronic pain conditions, including neuropathic pain, back pain, post-surgical pain, and migraine. For instance, in February 2024, Boston Scientific Corporation cleared U.S. Food and Drug Administration (FDA) approval for an expanded indication of the WaveWriter SCS Systems for the treatment of chronic low back and leg pain in people without prior back surgery, commonly referred to as non-surgical back pain (NSBP). The versatility of neurostimulation devices contributes to their dominance in the market as they cater to multiple patient needs with different pain profiles.

Advances in neurostimulation technology, such as minimally invasive implantation techniques, have made these devices more accessible and less intimidating for patients. The devices with a wearable approach that can be adjusted via smartphone, make it user-friendly and more acceptable to patients who may otherwise be resistant to invasive surgery.

For instance, in April 2023, Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, announced that it received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system. The system is comprised of a micro-implant that delivers neurostimulation therapy through a wireless platform including a wearable transmitter and iPad-based clinician programmer.

Geographical Analysis

North America is expected to hold a significant position in the pain management devices market share

North America especially the United States is home to several major players in the pain management devices market, including Medtronic, Stryker Corporation, Boston Scientific, Abbott and other emerging players. These companies have extensive R&D operations in the region, focusing on the development of advanced pain management solutions, resulting in innovations, which integrate advancements for personalized pain management.

For instance, in April 2024, Medtronic plc announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real-time, keeping therapy in harmony with the motions of daily life.

Additionally, in July 2024, Stryker launched the MultiGen 2 Radiofrequency (RF) Generator, this technology provides physicians with the efficiency, control and reliability they need when performing RF ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain. MultiGen 2 is the next generation of radiofrequency ablation that provides physicians with control and customization to perform chronic pain management procedures with confidence.

The U.S. FDA's rigorous but predictable approval process makes North America an ideal market for new pain management devices. Companies like Abbott and Boston Scientific frequently conduct pivotal clinical trials in North America to gain regulatory approval for new products. This gives North American patients early access to innovative pain relief technologies, fostering market leadership.

Asia-Pacific is growing at the fastest pace in the pain management devices market

Asia-Pacific is increasingly adapting global pain management technologies to local needs, leading to rapid market growth. For instance, the Abbott Proclaim XR system has been adapted for use in countries like India and China with specific features tailored to the local healthcare landscape. This device offers both spinal cord stimulation and peripheral nerve stimulation, making it suitable for a wide range of chronic pain conditions prevalent in the region.

The major market players and emerging players in the region developing advanced smart devices for pain management. For instance, in September 2022, UltrcareCare Pro introduced TENS 2.0, a Smart - Wearable, Wireless and Pocket-sized Pain Management Device for joint, muscular and everyday pain featuring a modern design that is truly wireless with the size of a smartwatch.

Increasing awareness of chronic pain and available treatments is driving market growth in APAC. Government and non-governmental organizations are conducting awareness campaigns about the benefits of pain management devices. For instance, in Australia, initiatives by Pain Australia have highlighted the benefits of devices like spinal cord stimulators and how they can improve the quality of life for chronic pain patients. These programs are educating both healthcare providers and patients, leading to higher adoption rates of pain management devices.

Competitive Landscape

The major global players in the pain management devices market include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Stryker Corporation, Nevro Corp, Aleva Neurotherapeutics, Zynex Inc., ICU Medical, Inc., inomed Medizintechnik GmbH, Enovis Corporation and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global pain management devices market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 187 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Application
• 2.5. Snippet by End-User
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Technological Advancements in Pain Management Devices
  • 3.1.2. Restraints
    • 3.1.2.1. High Cost of Pain Management Devices
  • 3.1.3. Opportunity
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. Emerging Startups and Key Innovators
• 4.3. CXO Perspectives
• 4.4. Latest Developments and Breakthroughs
• 4.5. Case Studies/Ongoing Research
• 4.6. Regulatory and Reimbursement Landscape
  • 4.6.1. North America
  • 4.6.2. Europe
  • 4.6.3. Asia Pacific
  • 4.6.4. Latin America
  • 4.6.5. Middle East & Africa
• 4.7. Porter's Five Force Analysis
• 4.8. Supply Chain Analysis
• 4.9. Patent Analysis
• 4.10. SWOT Analysis
• 4.11. Unmet Needs and Gaps
• 4.12. Recommended Strategies for Market Entry and Expansion
• 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.14. Pricing Analysis and Price Dynamics

5. Pain Management Devices Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Neurostimulation Devices*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Spinal Cord Stimulators
  • 5.2.4. Peripheral Nerve Stimulators
  • 5.2.5. Deep Brain Stimulators
• 5.3. Ablation Devices
  • 5.3.1. Cryoablation Devices
  • 5.3.2. Radiofrequency Ablation Devices
• 5.4. Infusion Pumps
• 5.5. Electrical Stimulation Devices

6. Pain Management Devices Market, By Application

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 6.1.2. Market Attractiveness Index, By Application
• 6.2. Neuropathic Pain*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Cancer Pain
• 6.4. Musculoskeletal Pain
• 6.5. Migraine Pain
• 6.6. Others

7. Pain Management Devices Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Homecare Settings
• 7.5. Physiotherapy Centers
• 7.6. Others

8. Pain Management Devices Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 8.2.7. U.S.
  • 8.2.8. Canada
  • 8.2.9. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 8.3.7. Germany
  • 8.3.8. U.K.
  • 8.3.9. France
  • 8.3.10. Spain
  • 8.3.11. Italy
  • 8.3.12. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 8.4.7. Brazil
  • 8.4.8. Argentina
  • 8.4.9. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 8.5.7. China
  • 8.5.8. India
  • 8.5.9. Japan
  • 8.5.10. South Korea
  • 8.5.11. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Medtronic plc*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
  • 10.1.5. SWOT Analysis
• 10.2. Boston Scientific Corporation
• 10.3. Abbott Laboratories
• 10.4. Stryker Corporation
• 10.5. Nevro Corp
• 10.6. Aleva Neurotherapeutics
• 10.7. Zynex Inc.
• 10.8. ICU Medical, Inc.
• 10.9. inomed Medizintechnik GmbH
• 10.10. Enovis Corporation

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us